Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
Recruiting · NCT04215809 · Registry updated 2025-04-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL | chronic lymphocytic leukemia/small lymphocytic lymphoma | Recruiting | Phase 1 | 2025-04-10 | NCT04215809 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Ascentage Pharma Group Inc. | 30 |
9 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope | Duarte | United States | 238 |
| Cleveland Clinic | Cleveland | United States | 558 |
| Dana Farber Cancer Institute | Boston | United States | 300 |
| Frankston Private Hospital | Melbourne | Australia | 1 |
| Gabrail Cancer Center | Canton | United States | 39 |
| Mayo Clinic | Jacksonville | United States | 122 |
| Novant Health | Charlotte | United States | 7 |
| Princess Alexandria Hospital | Brisbane | Australia | 1 |
| Swedish Health | Seattle | United States | 1 |